597 Project 1 - Santhosh Varadarajan Group 16 09/09/2009...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Santhosh Varadarajan Group 16 09/09/2009 Amgen Amgen is an international biotechnology company headquartered in Thousand Oaks, California . They are the largest independent biotech firm. Amgen discovers, develops and delivers innovative human therapeutics. The company has a manufacturing plant in Longmont, CO, a distribution center in Louisville, KY, and they have a global government affairs center in Washington, DC. The name Amgen stands for (Applied Molecular Genetics); this was taken as the official name of the company in 1983. Amgen has had multiple major corporate acquisitions. Some of these include: Synergen Inc. (1994), Immunex Corporation (2002), Abgenix Inc. (2006), and most recently Atlantos Pharmaceutical Holdings Inc. (2007). They have gone through three chief executive officers since its incorporation in 1980. In 2008 Amgen brought in a net income of about $3.166 billion, and invested $2.9 billion on R&D. In the last five years Amgen’s stock price had an initial value of about $59.18 a share, peaked at 84.86 in early 2005, then steadily fell to a minimum at $40.11 in early 2008. The minimum stock price in 2008 is most likely due to the recession. Today the stock price is exactly where it started off five years ago. The company has shown tremendous growth since its drop in 2008. Amgen’s principal products in the pharmaceutical field are Aranesp® (darbepoetin alfa), Enbrel® (etanercept), EPOGEN® (Epoetin alfa), Neulasta® (pegfilgrastim), and NEUPOGEN® (Filgrastim). Epogen and Neupogen were two of the most successful biopharmaceutical products of their time. Epogen is a glycoprotein that controls red blood cell production. Epogen is available as a therapeutic agent produced by recombinant DNA technology in mammalian cell culture . It is used in treating anaemia resulting from chronic kidney disease and from the treatment of cancer ( chemotherapy and radiation ), and from other critical illnesses ( heart failure ). EPOGEN total sales to date are $1,760 million and it will go off patent in 2009. Neupogen is used to treat neutropenia to stimulate the bone marrow to produce of neutrophils after chemotherapy. Neupogen total sales to date are $1,260 million, and it will go off patent in 2011. Amgen more than fifty molecules in phase three, there are five that are very new and innovative. These include Panitumumab, Cinacalcet, Motesaniv, Denosumab, and Darbepoetin alfa. These are all related to treatment of different types of cancer. They also have multiple
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 11/02/2009 for the course CHEM 597 taught by Professor Reklaitis during the Spring '09 term at Purdue University-West Lafayette.

Page1 / 4

597 Project 1 - Santhosh Varadarajan Group 16 09/09/2009...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online